Eli Lilly

Weight-loss drugs show signs of slowing biological aging, say drugmakers

Popular weight-loss drugs may do more than help people shed pounds. They might also melt away the years.

MIT Technology Review•Antonio Regalado17h ago

STAT+: Lilly’s Jaypirca approved as first-line CLL therapy

Eli Lilly’s Jaypirca has won FDA approval for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.

STAT•Meghana Keshavan5 Oct

Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.

CNBC2 Oct

• neutral toward Novo Nordisk · 97%

STAT+: Lilly bypasses Australian pharmacies with DTC model

Eli Lilly is launching LillyDirect to deliver Mounjaro straight to Australian patients’ doors — and local doctors and pharmacists aren’t thrilled.

STAT•Meghana Keshavan2 Oct

• neutral toward Eli Lilly · 87%

STAT+: Pharmalittle: We’re reading about a plan to lower Medicare drug prices, a Lilly obesity drug, and more

A final Medicare rule aimed at lowering prices for doctor-administered drugs applies to only four companies and saves 96% less than the initial proposal

STAT•Ed Silverman1 Oct

• neutral toward Eli Lilly · 93%

Weight-loss drug developers line up to tap lucrative market as competition heats up

The weight-loss drug market is booming, with biotech firms racing to capture a slice of the fast-growing sector dominated by Novo Nordisk and Eli Lilly.

Wall Street is closing out a strong quarter. Plus, Lilly's mixed obesity drug trial data

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

CNBC30 Sept

• neutral toward Eli Lilly · 98%

Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.

The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.

MarketWatch•Jaimy Lee30 Sept

• neutral toward Zepbound · 95%

Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.

CNBC30 Sept

• neutral toward Eli Lilly · 88%

STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial

An investigational combination therapy from Eli Lilly led to significant weight loss in a mid-stage study, but high discontinuation rates raise questions about tolerability.

STAT•Elaine Chen30 Sept

• critical toward Zepbound · 78%

New diabetes pill orforglipron achieves uniform weight loss for women of all ages

New analyses to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) show that the new daily oral weight loss / type 2 diabetes medication orforglipron was associated with…

Here are the 4 big things we're watching in the stock market in the week ahead

Both sides of the Fed's dual mandate are in focus. Plus, Micron reports and Eli Lilly delivers updates on its obesity pipeline.

CNBC27 Sept

‘It’s problematic’: concern as weight-loss jab maker sponsors Vogue World event

Critics say partnership between Mounjaro maker Eli Lilly and fashion giant suggests thinness is an aspiration The fifth iteration of Vogue World , overseen by Anna Wintour, took place in Milan on Tuesday night.

The Guardian•Chloe Mac Donnell27 Sept

Better storage buffers could pave way for safer mRNA therapies

Researchers at The University of Texas at Austin have teamed up with pharmaceutical leader Eli Lilly and Company to uncover new information about mRNA lipid nanoparticles (LNPs), the technology behind COVID-19 vaccines and other important treatments…

Freezing threatens mRNA delivery, but Tris buffer helps nanoparticles retain their potency

Researchers at The University of Texas at Austin have teamed up with pharmaceutical company Eli Lilly and Company to uncover how storage conditions affect mRNA lipid nanoparticles (LNPs), the technology behind COVID-19 vaccines and other treatments…

Phys.org25 Sept

STAT+: Lilly wins approval for once-weekly insulin shot

The FDA approved Eli Lilly’s Onswik, a once-weekly basal insulin for adults with type 2 diabetes, offering patients an alternative to daily long-acting insulin injections.

STAT•Meghana Keshavan25 Sept

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.

CNBC25 Sept

• critical toward Novo Nordisk · 91%
• favorable toward Eli Lilly · 90%

Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

CNBC24 Sept

• favorable toward Starbucks · 99%
• favorable toward Eli Lilly · 99%

STAT+: Pharmalittle: We’re reading about the FDA commissioner nominee, a Lilly partnership in China, and more

During a Senate hearing today, Heidi Overton, the nominee to lead the FDA, plans to emphasize the need for speed and efficiency to compete with China

STAT•Ed Silverman24 Sept

• neutral toward Fuji Dream Airlines · 99%

<a href="https://www.fiercebiotech.com/biotech/eli-lilly-puts-100m-plus-billions-backend-form-5-target-deal-innocare" hreflang="en">Lilly puts up $100M, plus billions on the backend, to form 5-target deal with InnoCare</a>

Eli Lilly has committed $100 million in upfront and near-term payments to InnoCare Pharma to form a five-target drug discovery pact. The deal features up to $3.25 billion in milestones.

Fierce Biotech•Nick Paul Taylor24 Sept